Skip to main content

Myeloma: Treating Blood Cancer as a Chronic Disease

This symposium was held during the Oncology Nursing Society’s (ONS) 48th Annual Congress on
April 28, 2023

Recording will be available soon.

Target Audience

This CE activity is intended for oncology nurses and nurse practitioners involved in the care of patients with hematologic malignancies.


Through interactive discussion and attendee feedback on patient cases, this symposium will provide an overview of FDA approved treatments and others being studied in clinical trials for myeloma, including oral therapy, systemic therapy, transplant, CAR T-cell therapy, and bispecific antibodies. The focus will be on the nurse’s role in administering treatment, side-effect management, educating and supporting patients, the role of the interdisciplinary team, and accessing resources for survivorship support. Disparities in diagnosis and treatment of Black Americans, low income, and other underserved populations, as well as issues that impede patients’ access to treatment will also be discussed. Attend this engaging, interactive, and fun symposium to learn more!

Learning Objectives

Upon completion, participants should be better able to:

  • Identify disparities in diagnosing myeloma and access to treatment
  • Explain treatment options and side-effect management, including newly approved and treatments in clinical trials
  • Describe the factors to consider when initiating and/or changing treatment, including challenges in adherence to treatment for myeloma as a chronic blood cancer
  • Explain goals of coordination among medical specialties to follow a plan of care throughout survivorship for myeloma and other chronic blood cancers
  • List resources to support patients and their caregivers


Krina K. Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Rhonda Hewitt, MSN, ANP, AOCNP
Hematology APP IV
Stanford Health Care
Stanford, CA

Continuing Education Information

For Nurses
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.


This activity is provided by The Leukemia & Lymphoma Society.

Meeting space was assigned to provide a Symposia supported by The Leukemia & Lymphoma Society during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26 – April 30, 2023 in San Antonio, TX. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.


There is no commercial support associated with this CE activity.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at